279 related articles for article (PubMed ID: 20615082)
1. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Nayak S; Shen M; Bunaciu RP; Bloom SE; Varner JD; Yen A
Leuk Lymphoma; 2010 Sep; 51(9):1734-47. PubMed ID: 20615082
[TBL] [Abstract][Full Text] [Related]
2. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
6. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
7. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
8. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
9. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
11. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide, a therapeutic agent for APL.
Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
[TBL] [Abstract][Full Text] [Related]
13. [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Zhou L; Chen G; Pan L
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):297-300. PubMed ID: 11798775
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Jing Y; Wang L; Xia L; Chen GQ; Chen Z; Miller WH; Waxman S
Blood; 2001 Jan; 97(1):264-9. PubMed ID: 11133770
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
[TBL] [Abstract][Full Text] [Related]
16. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Jing Y; Xia L; Lu M; Waxman S
Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
Sumi D; Suzukawa K; Himeno S
Life Sci; 2016 Mar; 149():42-50. PubMed ID: 26892147
[TBL] [Abstract][Full Text] [Related]
18. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
[TBL] [Abstract][Full Text] [Related]
19. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
20. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Jing Y; Xia L; Waxman S
Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
